AKT1 and endometrial cancer: MiR-302A-loaded UC-MSCs-Exo was reported to suppress the proliferation and migration of endometrial cancer cells by inhibiting the expression of cyclin D1 and the AKT signalling pathway during endometrial cancer treatment (114).